Results 41 to 50 of about 14,810 (242)

Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain [PDF]

, 2013
We demonstrated a role for the Mg2 + transporter TRPM7, a bifunctional protein with channel and α-kinase domains, in aldosterone signaling. Molecular mechanisms underlying this are elusive.
Yogi, A., Callera, G.E., O'Connor, S., Antunes, T.T., Valinsky, W., Miquel, P., Montezano, A.C.I., Perraud, A.-L., Schmitz, C., Shrier, A., Touyz, R.M.   +10 more
core   +2 more sources

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE

Рациональная фармакотерапия в кардиологии, 2015
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
B. B. Gegenava, O. M. Drapkina
doaj   +3 more sources

Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats

Annals of Hepatology, 2012
Background. Eplerenone is a selective mineralocorticoid receptor (MR) antagonist, and its potential protective role in cardiovascular injury has been reported by several studies. However, whether and how this drug can ameliorate hepatic injury in rats is
Ashraf Taye, Ihab T. Abdel-Raheem
doaj   +1 more source

Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure [PDF]

, 2014
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/102661/1/ejhf31 ...
Beck, Borlaug, Brilla, Burgess, Böhm, Chai, Chapman, Chatterjee, Cheng, Croom, Davies, Desai, Deswal, Edelmann, Fagart, Flack, Fletcher, Gardiner, Gasparo, Gerstein, Hernandez, Hollenberg, Iqbal, Jessup, Jeunemaitre, Joffe, Karagiannis, Kosmala, Krum, Kursaklioglu, Mak, Mansia, Maron, Martyniuk, McKelvie, McKenna, McKenna, McMurray, Michea, Parthasarathy, Pitt, Pitt, Pitt, Preiss, Ramirez-Gil, Rose, Saruta, Sato, Savoia, Sternon, Struthers, Swaminathan, Tamirisa, Tomova, Van Belle, Wakabayashi, Ward, Wei, Weinberger, White, Yamaji, Yamanaka, Yee, Zannad, Zannad, Zannad   +65 more
core   +2 more sources

Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT

Efficacy and Mechanism Evaluation, 2021
Background: In chronic central serous chorioretinopathy, fluid accumulates in the subretinal space and causes permanent vision loss in ≈ 30% of patients. There is no definitive treatment.
Andrew Lotery, Sobha Sivaprasad, Abby O’Connell, Rosie A Harris, Lucy Culliford, Angela Cree, Savita Madhusudhan, Helen Griffiths, Lucy Ellis, Usha Chakravarthy, Tunde Peto, Chris A Rogers, Barnaby C Reeves   +12 more
doaj   +1 more source

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +3 more sources

Oral eplerenone for the management of chronic central serous chorioretinopathy [PDF]

International Journal of Ophthalmology, 2015
AIM: To examine eplerenone (Inspra, Pfizer), a mineralocorticoid receptor antagonist, as a treatment option for chronic central serous chorioretinopathy (CSCR).
Rishi P Singh, Jonathan E Sears, Rumneek Bedi, Andrew P Schachat, Justis P Ehlers, Peter K Kaiser   +5 more
doaj   +1 more source

Effect of eplerenone in percutaneous coronary intervention‐treated post‐myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial [PDF]

, 2014
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107536/1/ejhf88 ...
Amano, Bacchetta, Beygui, Dickstein, Endemann, Fox, Hadoke, Hunt, Iqbal, Iqbal, Ishizawa, Jessup, Kayes-Wandover, Keeley, Keidar, Kursaklioglu, McMurray, O'Gara, Pitt, Pitt, Suzuki, Thum, Van Belle, Wakabayashi, Ward, Wijns, Wu, Zannad   +27 more
core   +2 more sources

Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan

International Journal of Hypertension, 2016
Prospective postmarketing surveillance of Selara (eplerenone), a selective mineralocorticoid receptor antagonist, was performed to confirm its safety and efficacy for hypertension treatment in Japan.
Shoko Takahashi, Megumi Hiramatsu, Shinichi Hotta, Yukie Watanabe, Osamu Suga, Yutaka Endo, Isamu Miyamori   +6 more
doaj   +1 more source

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature

International Journal of Retina and Vitreous, 2018
Purpose The purpose of this review is to examine the role of eplerenone in the treatment of central serous chorioretinopathy (CSCR). Methods A comprehensive search of the PubMed database has been conducted regarding eplerenone for CSCR, while studies ...
Irini Chatziralli, Aikaterini Vlachodimitropoulou, Chrysoula Daoula, Christina Vrettou, Eleni Galani, George Theodossiadis, Panagiotis Theodossiadis   +6 more
doaj   +1 more source